We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Epidermal Growth Factor Receptor Stimulates Early Cancer Metastasis

By LabMedica International staff writers
Posted on 15 Nov 2015
The stimulation of blood vessel formation by epidermal growth factor receptor (EGFR) early in tumor development was found to facilitate metastasis of the original tumor even before it was diagnosed.

Mutations that lead to EGFR overexpression have been associated with a number of cancers, including lung cancer, anal cancers, and the brain cancer glioblastoma multiforme. More...
Somatic mutations involving EGFR lead to its constant activation, which produces uncontrolled cell division.

Many malignant characteristics of cancer cells are regulated through pathways induced by the tyrosine kinase activity of EGFR. Investigators at the Scripps Research Institute (La Jolla, CA, USA) reported in a study that was published in the August 2015 issue of the journal Neoplasia that besides directly affecting the biology of cancer cells, EGFR also regulated the primary tumor microenvironment. Specifically, their findings demonstrated that both the expression and signaling activity of EGFR were required for the induction of a distinct intratumoral vasculature capable of sustaining tumor cell intravasation, an early step of metastatic dissemination during which tumor cells enter angiogenic blood vessels, which is a critical rate-limiting step in the metastatic cascade.

The investigators stated that this study unraveled an important but overlooked function of EGFR in cancer, namely, its ability to create an intravasation-sustaining microenvironment within the developing primary tumor by orchestrating several interrelated processes required for the initial steps of cancer metastasis through vascular routes. Their findings also suggested that EGFR-targeted therapies might be more effective when implemented in cancer patients with early-staged primary tumors containing a VEGF (vascular endothelial growth factor)-dependent angiogenic vasculature.

In experiments using chick embryos, the investigators found that EGFR signaling triggered a chain reaction inside tumor cells, ultimately resulting in the release of VEGF, known to be active in almost all forms of solid tumors. Released VEGF then bound to endothelial cells, inducing the growth of new blood capillaries and vessels within a developing tumor.

"When cancer cells have high levels of EGFR, the tumor has a lot of new, angiogenic blood vessels," said senior author Dr. Elena Deryugina assistant professor of cell and molecular biology at the Scripps Research Institute. "And these vessels are very welcoming for tumor cells and facilitate their dissemination from the very early stages of tumor development. Now we have learned that these newly formed vessels are used by tumor cells for dissemination because of their certain structural properties."

Related Links:
Scripps Research Institute



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.